BIT 5.26% 2.0¢ biotron limited

Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-561

  1. 405 Posts.
    lightbulb Created with Sketch. 39

    @Davisite. Look at MSB, in their phase 2 trial the data was promising for weaning off the LVAD, but in Phase 2b, they couldn’t replicate it. They didn’t even include

     any results of echocardiogram done in patients - unbelievable! That is unforgivable, to note release results of echocardiogram sin a trial for Heart failure.

    if you read the objective of phase 2a trial, it will become quit clear why thier stock crashed.

    hope thier phase 3 trial has better results as it would be life changing for many patients with endstage heart failure who die waiting transplants.

 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.